Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Abbv    crawled time : 14:12    save search
RINVOQ™ (upadacitinib) Achieved Superiority Versus DUPIXENT® (dupilumab) For Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis
Published: 2020-12-10 (Crawled : 14:12) - prnewswire.com
ABBV | $164.25 1.05% -0.76% 4M twitter stocktwits trandingview |
Health Technology
 | | O: 0.36% H: 0.01% C: -1.44%
dermatitis phase 3 atopic dermatitis dupixent
Gainers vs Losers
57% 43%

Top 10 Gainers
INVO | $1.82 139.47% 56.82% 220M twitter stocktwits trandingview |
Health Technology
SINT | $0.0365 59.39% 37.26% 470M twitter stocktwits trandingview |
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M twitter stocktwits trandingview |
Electronic Technology
EDBL | News | $6.66 46.37% 32.39% 13M twitter stocktwits trandingview |

GCTK | $0.715 36.27% 26.62% 600K twitter stocktwits trandingview |
Manufacturing
TCON | $2.33 36.26% 26.61% 2M twitter stocktwits trandingview |
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M twitter stocktwits trandingview |

KZIA | $0.3442 18.28% 23.42% 290K twitter stocktwits trandingview |
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M twitter stocktwits trandingview |
Health Technology
ATNF | $1.91 29.05% 22.51% 310K twitter stocktwits trandingview |

Your saved searches
Save your searches and get alerts when important news are released.